Jan Smeitink

Jan Smeitink

Auto-generated profile, based on publicly available information

Jan Smeitink

Khondrion BV

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Cell Metabolism
Verified
Journal Article
Closed access
TSTom J.J. Schirris
Tom J.J. Schirris
HRHerma Renkema
Herma Renkema
TRTina Ritschel
Tina Ritschel
NVNicol C. Voermans
Nicol C. Voermans
ABAlbert Bilos
Albert Bilos
FRFrans G.M. Russel
Frans G.M. Russel

8 March 2016 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
WKWerner Jh Koopman
Werner Jh Koopman
JBJulien Beyrath
Julien Beyrath
CFCheuk‐Wing Fung
Cheuk‐Wing Fung
SKSaskia Koene
Saskia Koene
RRRichard Rodenburg
Richard Rodenburg
JSJan Am Smeitink
Jan Am Smeitink
This review presents our current understanding of the pathophysiology and potential treatment strategies with respect to mitochondrial disease in children. We focus on pathologies due to mutations in nuclear DNA‐encoded structural and assembly factors of the mitochondrial oxidative phosphorylation (OXPHOS) system, with a particular emphasis on isolated mitochondrial complex I deficiency. Following a brief introduction into mitochondrial disease and OXPHOS function, an overview is provided of the diagnostic process in children with mitochondrial disorders. This includes the impact of whole‐exome sequencing and relevance of cellular complementation studies. Next, we briefly present how OXPHOS mutations can affect cellular parameters, primarily based on studies in patient‐derived fibroblasts, and how this information can be used for the rational design of small‐molecule treatment strategies. Finally, we discuss clinical trial design and provide an overview of small molecules that are currently being developed for treatment of mitochondrial disease. See also: A Suomalainen (October 2015)

28 February 2002 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MSMarkus Schuelke
Markus Schuelke
HKHeiko Krude
Heiko Krude
BFBarbara Finckh
Barbara Finckh
EMErtan Mayatepek
Ertan Mayatepek
AJAntoon Janssen
Antoon Janssen
JSJan Smeitink
Jan Smeitink

26 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JBJulien Beyrath
Julien Beyrath
MPMina Pellegrini
Mina Pellegrini
HRHerma Renkema
Herma Renkema
LHLisanne Houben
Lisanne Houben
SPSvetlana Pecheritsyna
Svetlana Pecheritsyna
JSJan A. M. Smeitink
Jan A. M. Smeitink
A deficient activity of one or more of the mitochondrial oxidative phosphorylation (OXPHOS) enzyme complexes leads to devastating diseases, with high unmet medical needs. Mitochondria, and more specifically the OXPHOS system, are the main cellular production sites of Reactive Oxygen Species (ROS). Increased ROS production, ultimately leading to irreversible oxidative damage of macromolecules or to more selective and reversible redox modulation of cell signalling, is a causative hallmark of mitochondrial diseases. Here we report on the development of a new clinical-stage drug KH176 acting as a ROS-Redox modulator. Patient-derived primary skin fibroblasts were used to assess the potency of a new library of chromanyl-based compounds to reduce ROS levels and protect cells against redox-stress. The lead compound KH176 was studied in cell-based and enzymatic assays and in silico. Additionally, the metabolism, pharmacokinetics and toxicokinetics of KH176 were assessed in vivo in different animal species. We demonstrate that KH176 can effectively reduce increased cellular ROS levels and protect OXPHOS deficient primary cells against redox perturbation by targeting the Thioredoxin/Peroxiredoxin system. Due to its dual activity as antioxidant and redox modulator, KH176 offers a novel approach to the treatment of mitochondrial (-related) diseases. KH176 efficacy and safety are currently being evaluated in a Phase 2 clinical trial.

15 December 2012 in Antioxidants & Redox Signaling
Verified
Journal Article
Open access
FDFelix Distelmaier
Felix Distelmaier
FVFederica Valsecchi
Federica Valsecchi
MFMarleen Forkink
Marleen Forkink
SVSjenet van Emst-De Vries
Sjenet van Emst-De Vries
HSHerman G. Swarts
Herman G. Swarts
WKWerner J.H. Koopman
Werner J.H. Koopman
Aims: Cell regulation by signaling reactive oxygen species (sROS) is often incorrectly studied through extracellular oxidant addition. Here, we used the membrane-permeable antioxidant Trolox to examine the role of sROS in mitochondrial morphology, oxidative phosphorylation (OXPHOS), and cytosolic calcium (Ca2+) handling in healthy human skin fibroblasts. Results and Innovation: Trolox treatment reduced the levels of 5-(and-6)-chloromethyl-2′,7′-dichlorodihydro-fluorescein (CM-H2DCF) oxidizing ROS, lowered cellular lipid peroxidation, and induced a less oxidized mitochondrial thiol redox state. This was paralleled by increased glutathione- and mitofusin-dependent mitochondrial filamentation, increased expression of fully assembled mitochondrial complex I, elevated activity of citrate synthase and OXPHOS enzymes, and a higher cellular O2 consumption. In contrast, Trolox did not alter hydroethidium oxidation, cytosolic thiol redox state, mitochondrial NAD(P)H levels, or mitochondrial membrane potential. Whole genome expression profiling revealed that Trolox did not trigger significant changes in gene expression, suggesting that Trolox acts downstream of this process. Cytosolic Ca2+ transients, induced by the hormone bradykinin, were of a higher amplitude and decayed faster in Trolox-treated cells. These effects were dose-dependently antagonized by hydrogen peroxide. Conclusions: Our findings suggest that Trolox-sensitive sROS are upstream regulators of mitochondrial mitofusin levels, morphology, and function in healthy human skin fibroblasts. This information not only facilitates the interpretation of antioxidant effects in cell models (of oxidative-stress), but also contributes to a better understanding of ROS-related human pathologies, including mitochondrial disorders. Antioxid. Redox Signal. 17, 1657–1669.

3 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MFMarisa W. Friederich
Marisa W. Friederich
STSharita Timal
Sharita Timal
CPChristopher A. Powell
Christopher A. Powell
CDCristina Dallabona
Cristina Dallabona
AKAlina Kurolap
Alina Kurolap
JHJohan L. K. Van Hove
Johan L. K. Van Hove
Mitochondrial protein synthesis requires charging mt-tRNAs with their cognate amino acids by mitochondrial aminoacyl-tRNA synthetases, with the exception of glutaminyl mt-tRNA (mt-tRNAGln). mt-tRNAGln is indirectly charged by a transamidation reaction involving the GatCAB aminoacyl-tRNA amidotransferase complex. Defects involving the mitochondrial protein synthesis machinery cause a broad spectrum of disorders, with often fatal outcome. Here, we describe nine patients from five families with genetic defects in a GatCAB complex subunit, including QRSL1, GATB, and GATC, each showing a lethal metabolic cardiomyopathy syndrome. Functional studies reveal combined respiratory chain enzyme deficiencies and mitochondrial dysfunction. Aminoacylation of mt-tRNAGln and mitochondrial protein translation are deficient in patients’ fibroblasts cultured in the absence of glutamine but restore in high glutamine. Lentiviral rescue experiments and modeling in S. cerevisiae homologs confirm pathogenicity. Our study completes a decade of investigations on mitochondrial aminoacylation disorders, starting with DARS2 and ending with the GatCAB complex.